Cargando…
Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report
Checkpoint inhibitors have gained increased traction in recent years as they have improved prognosis in various malignancies. Pembrolizumab, an anti-programmed cell death protein (PD-1) monoclonal antibody, has become a first-line chemotherapeutic agent for stage II non–small cell lung cancer since...
Autores principales: | Khatri, Shivam, Alom, Mulham, Kashfi, Simon, Atallah, Jane, Goswami, Gayotri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467221/ https://www.ncbi.nlm.nih.gov/pubmed/37642143 http://dx.doi.org/10.1177/23247096231194401 |
Ejemplares similares
-
Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen
por: Figueroa-Perez, Nikole, et al.
Publicado: (2021) -
Two Cases of Pembrolizumab-Induced Secondary Adrenal Insufficiency
por: Kanzaki, Akinori, et al.
Publicado: (2021) -
Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report
por: Oristrell, Gerard, et al.
Publicado: (2018) -
FRI396 Coexisting Secondary Selective Adrenal Insufficiency And Primary Hypothyroidism In A Patient Previously Treated With Pembrolizumab As Breast Cancer Therapy
por: Mayers, Raisa Amelia
Publicado: (2023) -
LBODP011 Pembrolizumab Induced Hypophysitis And Resultant Isolated ACTH Deficiency Presenting As Secondary Adrenal Insufficiency.
por: Arora, Gunjan, et al.
Publicado: (2022)